When oral morphine fails in cancer pain: The role of the alternative routes

American Journal of Hospice and Palliative Medicine

Volumn 15, Issue 6, 1998, Pages 333-342

  Mercadante, Sebastiano G ^a  

^a SAMOT Onlus   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; NARCOTIC ANALGESIC AGENT;

DRUG ADMINISTRATION ROUTE; HUMAN; NEOPLASM; PAIN; REVIEW; TREATMENT FAILURE;

ANALGESICS, OPIOID; DRUG ADMINISTRATION ROUTES; HUMANS; MORPHINE; NEOPLASMS; PAIN; TREATMENT FAILURE;

EID: 0032201516     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990919801500607     Document Type: Article

References (88)

1. Hanks GW, De Conno F, Ripamonti C, et al: Morphine in cancer pain: modes of administration. BMJ. 1996;312:823-826.
2. Coyle N, Adelhardt J, Foley KM, et al: Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage. 1990;5:83-93.
3. Cherny NJ, Chang V, Frager G, et al: Opioid pharmacotherapy in the management of cancer pain. Cancer. 1995;76:1288-1293.
4. Mercadante S, Genovese G, Kargar JA, et al: Home palliative care: results in 1991 versus 1988. J Pain Symptom Manage. 1992;7:414-418.
5. Bruera E: Alternate routes for home opioid therapy. Pain Clinical Updates. 1993;1:1-4.
6. McDonald P, Graham P, Clayton M, et al: Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer. Palliat Med. 1991;5:323-329.
7. Drexel H, Dzien A, Spiegel RW, et al: Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain. 1989;36:169-176.
8. Bruera E, Ripamonti C: Alternate routes of administration of opioids. In Patt RB (ed.): Cancer pain. Philadelphia, JB Lippincott Co., 1993; 161-184.
9. Coyle N, Cherny NI, Portenoy RK: Subcutaneous opioid infusions at home. Oncology. 1994;8:31-32.
10. Moulin DE, Kreeft JH, Murray-Parsons N, et al: Comparison of continuous subcutaneous hydromorphone infusions for management of cancer pain. Lancet. 1991;337:465-468.
11. Waldman CS, Eason JR, Rambohul E, et al: Serum morphine levels: a comparison between continuous subcutaneous infusion and continuous intravenous infusion in postoperative patients. Anesthesia. 1984;39:768-771.
12. Nelson KA, Glare PA, Walsh D, et al: A prospective, within-patient, cross-over study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manage. 1997;13:262-267.
13. Mercadante S: Pain treatment and outcome in advanced cancer patients followed at home. Cancer. In press.
14. Grond S, Zech D, Schug SA, et al: Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage. 1991;6:411-422.
15. Schug SA, Zech D, Grond S, et al: A long term survey of morphine in cancer pain patients. J Pain Symptom Manage. 1992;7:259-266.
16. Zech DFJ, Grond S, Lynch J, et al: Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63:65-76.
17. Tiseo PJ, Thaler HT, Iapin J, et al: Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain. 1995;61:47-54.
18. Mercadante S: The role of morphine metabolites in cancer pain. Palliat Med. In press.
19. Kalso E, Heiskanen T, Rantio M, et al: Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain. 1996;67:443-449.
20. Glare P: Problems with opiates in cancer pain: parenteral opioids. Support Care Cancer. 1997;5:445-450.
21. Singer M, Noonan KR: Continuous intravenous infusion of fentanyl: case reports of use in patients with advanced cancer and intractable pain. J Pain Symptom Manage. 1993;8:215-220.
22. Paix A, Coleman A, Lees J, et al: Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain. 1995;63:263-269.
23. Mercadante S, Caligara M, Sapio M, et al: Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. J Pain Symptom Manage. 1997;13:241-244.
24. Bruera E, Fainsinger RL, Moore M, et al: Local toxicity with subcutaneous methadone. Experience of two centers. Pain. 1991;45:141-143.
25. De Conno F, Ripamonti C, Saita L, et al: Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol. 1995;13:1004-1008.
26. Gorman DJ: Opioid analgesics in the management of pain in patients with cancer: an update. Palliat Med. 1991;5:277-294.
27. Warren D: Practical use of rectal medications in palliative care. J Pain Symptom Manage. 1996;11:378-387.
28. Campbell WI: Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST continuous 100 mg. J Clin Pharm Ther. 1996;21:65-71.
29. Maloney CM, Kesner RK, Klein G, et al: The rectal administration of MS Contin: clinical implications of use in end stage cancer. Am J Hosp Care. 1989;6:34-35.
30. Babul N, Darke AC, Anslow JA, et al: Pharmacokinetics of two novel rectal controlled-release morphine formulations. J Pain Symptom Manage. 1992;7:400-405.
31. Kaiko RF, Fitsmartin RD, Thomas GB, et al: The bioavailability of morphine in controlled-release 30 mg tables per rectum compared with immediate-release 30 mg rectal suppositories and controlled-release 30 mg oral tablets. Pharmacotherapy. 1992;12:107-113.
32. Babul N, Darke AC: Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. Clin Pharmacol Ther. 1993;54:286-292.
33. Leow KP, Smith MT, Eatt JA, et al: Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit. 1991;14:479-484.
34. Ripamonti C, Zecca E, Brunelli C, et al: Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol. 1995;6:841-843.
35. Bruera E, Watanabe S, Fainsinger RL, et al: Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain. 1995;62:141-146.
36. Portenoy RK, Southam M, Gupta SK, et al: Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology. 1993;78:36-43.
37. Lehmann KA, Zech D: Transdermal fentanyl. J Pain Symptom Manage. 1992;7:8-16.
38. MacDonald N: Commentary. J Pain Symptom Manage. 1993;8:320-321.
39. Bruera E, Pereira J, Watanabe S, et al: Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996;78:852-857.
40. Zech D, Grond S, Lynch J, et al: Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain. 1992;50:293-301.
41. Donner B, Zenz M, Tryba M, et al: Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64:527-534.
42. Korte W, de Stoutz N, Morant R: Day-today titration to initiate transdermal fentanyl in patients with cancer pain: Short- and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage. 1996;11:139-146.
43. Patt B: Commentary. J Pain Symptom Manage. 1993;8:322-323.
44. Hanks GW, Fallon MT: Transdermal fentanyl in cancer pain: conversion from oral morphine. J Pain Symptom Manage. 1995;10:87.
45. Ahmedzai S, Brooks D: TTS-Fentanyl Comparative Trial Group. Transdermal fentanyl versus sustained release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage. 1997;13:254-261.
46. The TTS-Fentanyl Multicentre Study Group. Transdermal fentanyl in cancer pain. J Drug Dev. 1994;6:93-97.
47. Hunt R: Transdermal fentanyl and the opioid withdrawal syndrome. Palliat Med. 1994;4:347-348.
48. Davies AN, Bond C: Transdermal fentanyl and the opioid withdrawal syndrome. Palliat Med. 1994;4:348.
49. Grond S, Zech D, Lehmann KA, et al: Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain. 1997;69:191-198.
50. Zenz M, Donner B, Strumpf M: Withdrawal symptoms during therapy with transdermal fentanyl? J Pain Symptom Manage. 1994;9:54-55.
51. Jeal W, Benfield P: Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997;53:109-138.
52. Stanley TH, Ashburn MA: Novel delivery systems: oral transmucosal and intranasal transmucosal. J Pain Symptom Manage. 1992;7:163-171.
53. Weinberg DS, Inturrisi CE, Redenberg B, et al: Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther. 1988;44:335-342.
54. Osborne R, Joel S, Trew D, et al: Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-metabolite. Clin Pharmacol Ther. 1990;47:12-19.
55. Robinson JM, Wilkie DJ, Campbell B: Sublingual and oral morphine administration. Nurs Clin North Am. 1995;30:725-743.
56. Mercadante S: Letter. J Palliat Care. 1992;8:51-52.
57. Manara AR, Shelly MP, Quinn KG, et al: Pharmacokinetics of morphine following administration by the buccal route. Br J Anaesth. 1989;62:498-502.
58. Cleary JF: Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Semin Oncol. 1997;24 (suppl. 16): 13-16.
59. Kunz KM, Theisen JA, Schoeder ME: Severe episodic pain: management with sublingual sufentanil. J Pain Symptom Manage. 1993;8:189.
60. Striebel HW, Oelmann T, Spies C, et al: Patient-controlled intranasal analgesia: a method for noninvasive postoperative pain management. Anesth Analg. 1996;83:548-551.
61. Fine PG, Marcus M, De Boer AJ, et al: An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain. 1991;45:149-153.
62. Fine PG: Fentanyl in the treatment of cancer pain. Semin Oncol. 1997;24(suppl. 16): 20-27.
63. Maasod AR, Thomas SH: Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. Br J Clin Pharmacol. 1996: 41:250-252.
64. Zeppetella G: Nebulized morphine in the palliation of dyspnea. Palliat Med. 1997;11:267-275.
65. Davis CL, Penn K, A'Hern R, et al: Single-dose randomized controlled trial of nebulized morphine in patients with cancer-related breathlessness. Palliat Med. 1996;10:64-65.
66. Quelch PC, Faulkner DE, Yun JWS: Nebulized opioids in the management of dyspnea. J Palliat Care. 1997;13:48-52.
67. Farncombe M, Chatter S, Gillin A: The use of nebulized opioids for breathlessness: a chart review. Palliat Med. 1994;8:306-312.
68. Lang E, Jedeikin R: Acute respiratory depression as a complication of nebulised morphine. Can J Anaesth. 1998;45:60-62.
69. Mercadante S, Agnello A, Armata MG, et al: The inappropriate use of the epidural route in cancer pain. J Pain Symptom Manage. 1997;13:352-355.
70. Hogan Q, Haddox JD, Abram S, et al: Epidural opiates and local anesthetics for the management of cancer pain. Pain. 1991: 46:271-279.
71. Zech DFJ, Grond S, Lynch J, et al: Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63:65-76.
72. Samuelsson H, Malberg F, Eriksson M, et al: Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage. 1995;10:105-112.
73. van Dongen RTM, Crul BJP, De Bock M: Long-term intrathecal infusion of morphine and morphine/bupivacaine mixtures in the treatment of cancer pain: a retrospective analysis of 51 cases. Pain. 1993;55:119-123.
74. Krames ES: Intrathecal infusional therapies for intractable pain: patient management guidelines. J Pain Symptom Manage. 1993;8:36-46.
75. Du Pen SL, Williams AR: The dilemma of conversion from systemic to epidural morphine: a proposed conversion tool for treatment of cancer pain. Pain. 1994;56:113-118.
76. Gourlay GK, Plummer JL, Cherry DA, et al: Comparison or intermittent bolus with continuous infusion of epidural morphine in the treatment of severe cancer pain. Pain. 1991;47:135-140.
77. Nitescu P, Sjoberg M, Appelgren L, et al: Complications of intrathecal opioids and bupivacaine in the treatment of "refractory" cancer pain. Clin J Pain. 1995;11:45-62.
78. Gesten Y, Vainio A, Pégurier AM: Long-term intrathecal infusion of morphine in the home care of patients with advanced cancer. Acta Anaesthesiol Scand. 1997;47:12-17.
79. Crul BJ, Delhaas EM: Technical complications during long-term subarachnoid or epidural administration of morphine in terminally ill cancer patients: a review of 140 cases. Reg Anesth. 1991;16:209-213.
80. Nitescu P, Appelgren L, Linder LE, et al: Epidural versus intrathecal morphine-bupivacaine: assessment of consecutive treatments in advanced cancer pain. J Pain Symptom Manage. 1990;5:18-26.
81. Sjoberg H, Karlsson P, Nordborg C, et al: Neuropathologic findings after long-term intrathecal infusions of morphine and bupivacaine for pain treatment in cancer patients. Anesthesiology. 1992;76:173-186.
82. Appelgren L, Nordborg C, Sjoberg M, et al: Spinal epidural metastasis: implications for spinal analgesia to treat "refractory" cancer pain. J Pain Symptom Manage. 1997;13:25-42.
83. Chrubasik J, Chrubasik S, Martin E: The ideal epidural opioid: fact or fantasy. Eur J Anaesth. 1993;10:79-100.
84. Amer S, Amer B: Differential effects of epidural morphine in the treatment of cancer related pain. Acta Anesthesiol Scand. 1985;29:32-36.
85. Samuelsson H, Hedner T: Pain characterization in cancer patients and the analgesic response to epidural morphine. Pain. 1991;46:3-8.
86. Erdine S, Aldemir T: Long-term results of peridural morphine in 225 patients. Pain. 1991;45:155-159.
87. Mercadante S: Controversies in the spinal treatment in advanced cancer patients. Support Care Cancer. In press.
88. Karavelis A, Forogiou G, Selviaridis P, et al: Intraventricular administration of morphine for control of intractable cancer pain in 90 patients. Neurosurgery. 1996;39:57-62.